In their letter in the December 2010 issue, “Author Response: Bevacizumab Suppression of Establishment of Micrometastases in Experimental Ocular Melanoma” Yang et al.
1 state that “bevacizumab has been used in mouse models of choroidal neovascularization” and quote Hua et al.,
2 for which I am the corresponding author. This is an incorrect and misleading reference. We certainly did not show that bevacizumab affected mouse models of choroidal neovascularization, only that it inhibited human VEGF165-mediated migration of endothelial cells at the same dose-response as VEGF165b.